Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019 Year: 2020
Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Effectiveness of intravenous isoniazid and ethambutol administration in patients with new smear positive drug-susceptible pulmonary tuberculosis with tuberculous meningoencephalitis and HIV co-infection in the intensive phase of treatment Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
Transthyretin in patients with pulmonary tuberculosis co-infected HIV. Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021
Particularities of tuberculosis at children hospitalized with HIV co-infection Source: Annual Congress 2009 - Tuberculosis at different age groups Year: 2009
Characteristics of tuberculosis patients co-infected with COVID-19 Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities Year: 2021
Direct molecular testing for isoniazid and rifampicin resistance from respiratory specimens of patients with tuberculosis Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013
Bedaquiline in the treatment of patients with co-infection HIV/tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018
Multi drug resistant (rifampicin + isoniazid) pulmonary tuberculosis – a challenge for a developing country specially co-infected with HIV Source: Eur Respir J 2007; 30: Suppl. 51, 421s Year: 2007
Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients Source: Eur Respir J 2015; 46: 271-274 Year: 2015
Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs Source: Eur Respir J, 55 (3) 1902048; 10.1183/13993003.02048-2019 Year: 2020
The tuberculosis in patients with HIV and AIDS Source: Eur Respir J 2007; 30: Suppl. 51, 656s Year: 2007
High rate of hepatitis due to treatment with pyrazinamide (PYR) and ethambutol (EMB) for latent tuberculosis infection (LTBI) in subjects exposed to MDR-TB Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities Year: 2005
Primary drug resistance of mycobacterium tuberculosis in HIV-positive patients Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA) Year: 2016
The (in)significance of TB and COVID-19 co-infection Source: Eur Respir J, 56 (2) 2002105; 10.1183/13993003.02105-2020 Year: 2020
Anti tubercular chemoprophylaxis regimens in HIV seropositives with latent tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 566s Year: 2002
Bedaquiline in treatment of TB/HIV co-infection patients with extremely-drug resistance of MBT Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018
Evaluation of the multidrug resistant TB in children with HIV infection Source: Eur Respir J 2004; 24: Suppl. 48, 439s Year: 2004
The impact of bedaquiline and delamanid containing regimens on liver function in patients multi-infected with pulmonary DR-TB, HIV and viral hepatitis Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
Prevalence of HIV infection among tuberculosis cases and pattern of tuberculosis and treatment outcome in HIV seropositives – a study from a tuberculosis center from India Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009